Updates on Johnson & Johnson

By
-
1
77

Arkansas judge Tim Fox, who ruled earlier this year that Janssen Pharmaceuticals and its parent company Johnson & Johnson had concealed risks associated with their antipsychotic Risperdal and levied a fine of $1.2 billion, has denied a J&J request for a new trial. In other news, sources say that J&J is within two weeks of a final settlement with federal prosecutors to resolve allegations of using deceptive tactics to market Risperdal. J&J hopes to avoid a felony charge that would prevent it from marketing Risperdal to government health programs such as medicare.

***

Mad in America hosts blogs by a diverse group of writers. These posts are designed to serve as a public forum for a discussion—broadly speaking—of psychiatry and its treatments. The opinions expressed are the writers’ own.

***

Mad in America has made some changes to the commenting process. You no longer need to login or create an account on our site to comment. The only information needed is your name, email and comment text. Comments made with an account prior to this change will remain visible on the site.

Previous articleBritish Psychological Society Critiques the DSM-5
Next article“Zoloft Defense” Defendant Testifies on His Own Behalf
Kermit Cole
Kermit Cole
Kermit Cole, MFT, founding editor of Mad in America, works in Santa Fe, New Mexico as a couples and family therapist. Inspired by Open Dialogue, he works as part of a team and consults with couples and families that have members identified as patients. His work in residential treatment — largely with severely traumatized and/or "psychotic" clients — led to an appreciation of the power and beauty of systemic philosophy and practice, as the alternative to the prevailing focus on individual pathology. A former film-maker, he has undergraduate and master's degrees in psychology from Harvard University, as well as an MFT degree from the Council for Relationships in Philadelphia. He is a doctoral candidate with the Taos Institute and the Free University of Brussels. You can reach him at [email protected].

1 COMMENT

  1. Risperdal reproached.
    Same saga here as Eli Lilly Zyprexa.
    Johnson and Johnson is a trusted brand we associate with babies.
    Risperdal,Zyprexa,as well as the other atypical antipsychotics, are being prescribed for children, even though this is an unapproved, off-label use. An estimated 2.5 million children are now taking atypical antipsychotics. Over half are being given them for Attention Deficit Hyperactivity Disorder,many of these foster children.
    Weight gain, increases in triglyceride levels and associated risks for (life-long) diabetes and cardiovascular disease.
    Eli Lilly made $65 BILLION on Zyprexa!
    *Tell the truth don’t be afraid*
    Daniel Haszard FMI
    http://www.zyprexa-victims.com

    Report comment

LEAVE A REPLY